According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Pulmonary hypertension
PH and lung diseases
- Contact eczema
Causes and prevention at work
- Respiratory infections: viral bronchitis or bacterial pneumonia?
Old crucial question in the light of current findings
- What biomarkers reveal about "biological youth" - and what not (yet)
Epigenetic ageing
- Amyotrophic lateral sclerosis and nutrition
Calorie optimization in ALS through digital intervention
- "Forgotten axis" between plant substances, gut and systemic health
Microbiome and phytotherapy
- HIV: updated EACS guideline
Individualized approach to sustainable prevention and care
- Evidence-based diagnostics and treatment in the medical setting